MedTrace Logo

Vitamin D3 Treatment and Homocysteine Concentrations Among Overweight Reproductive Women

NCT03310307 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-10-16

No results posted yet for this study

Summary

100 overweight reproductive vitamin D deficient women were divided into two groups; vitamin D (n = 50) and placebo (n = 50). Vitamin D group received treatment dose of 50,000 IU of vitamin D3 per week for 2 consecutive months and placebo group received placebo tablets similar in size, shape and color to vitamin D3 for 2 months also. Total homocysteine concentrations were measured before intervention (basal), on 30 days (one month) and on 60 days (2 months) of intervention. Changes in means of homocysteine concentrations for placebo and vitamin D group over time showed significant difference on 30 and 60 days of intervention. Mean comparisons of homocysteine concentrations and standard error of the means before and after intervention showed statistical significant decrease in homocysteine concentrations among vitamin D group.

Conditions

  • Homocystinaemia
  • Vitamin D Deficiency

Interventions

DRUG

Vit D

50,000 IU

OTHER

Placebo

Sponsors & Collaborators

  • Jordan University of Science and Technology

    collaborator OTHER

  • Al-Balqa Applied University

    lead OTHER

Principal Investigators

  • Jehan M Hamadneh, FRCOG · JUST

  • Nahla S Al-Bayyari, PhD · BAU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-01
Primary Completion
2016-08-30
Completion
2016-10-30

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03310307 on ClinicalTrials.gov